Biocon Q4 results show Consolidated revenue up by 21% - The Statesman
Branding Asia's premier biotechnology company - TSK Design
Biocon Biologics enters licensing agreement with Yoshindo of Japan - The Hindu BusinessLine
Biocon in pact with Japan's Yoshindo to commercialise two biosimilar assets | Mint
Biocon subsidiary acquires Viatris pharma for $3 billion | Mint
Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs - Biocon
Research Centre - Biocon
Biocon's pre-tax profit rises 9% to Rs 315 crore in Oct-Dec quarter | Business Standard News
Biocon Academy - Biocon
Biocon logo in transparent PNG format
BIOCON Stock Price and Chart — NSE:BIOCON — TradingView
Covid has created an 'ecosystem' of innovation in India, says Biocon chief Kiran Mazumdar-Shaw | Mint
Biocon Campus - Biocon
Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
True North to acquire 2.4% stake in Biocon Biologics at a valuation of $3 billion | Mint
Fortune India: Business News, Strategy, Finance and Corporate Insight
Biocon Biologics, Serum Institute Life Sciences enter strategic alliance
Syngene International: Biocon sells 5.4% stake in arm Syngene International - The Economic Times
Cash-and-stock deal: Biocon Biologics acquires Viatris for $3.33 billion | The Financial Express
Biocon - Wikipedia
Biocon Biologics Limited | ISPE | International Society for Pharmaceutical Engineering
Biocon sells 5.4% stake in its research arm Syngene International - Hindustan Times
Research Centre - Biocon
Biocon Biologics' antibody drug unit in Bengaluru gets EU GMP certificate | Business Standard News
Biocon biosimilar plant criticized again by the FDA | Fierce Pharma
Manufacturing Operations - Biocon - Global Biopharmaceutical company
